Marilyn N. Martinez , Jonathan P. Mochel , Pierre-Louis Toutain
{"title":"Evolving value and validity of animal models in veterinary therapeutic research: Impact of scientific progress","authors":"Marilyn N. Martinez , Jonathan P. Mochel , Pierre-Louis Toutain","doi":"10.1016/j.ejps.2025.107111","DOIUrl":null,"url":null,"abstract":"<div><div>In veterinary medicine, experimental <em>in vivo</em> animal models have long been integral to advancing our understanding of disease mechanisms and assessing the safety and efficacy of potential therapies. However, the value and validity of these models warrants reassessment in light of emerging scientific evidence, evolving standards in animal welfare, and the development of alternative methodologies. Such a reassessment is essential for maintaining ethical scientific practices and ensuring that research approaches remain both relevant and justifiable, especially as our awareness of animal pain, sentience, and consciousness deepens. While interspecies extrapolation of findings from these models poses challenges when applied to human medicine, what about cases where an animal species serves as both the experimental subject and the intended veterinary patient? Additionally, what alternative tools are potentially available to replace <em>in vivo</em> studies in these contexts? This commentary explores how veterinary research may improve efforts to meet the principles of the 3R’s by integrating alternative <em>in vitro</em> and <em>in silico</em> models early in the investigative process and utilizing specialized tools within the target veterinary population during clinical trials.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"210 ","pages":"Article 107111"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725001101","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
In veterinary medicine, experimental in vivo animal models have long been integral to advancing our understanding of disease mechanisms and assessing the safety and efficacy of potential therapies. However, the value and validity of these models warrants reassessment in light of emerging scientific evidence, evolving standards in animal welfare, and the development of alternative methodologies. Such a reassessment is essential for maintaining ethical scientific practices and ensuring that research approaches remain both relevant and justifiable, especially as our awareness of animal pain, sentience, and consciousness deepens. While interspecies extrapolation of findings from these models poses challenges when applied to human medicine, what about cases where an animal species serves as both the experimental subject and the intended veterinary patient? Additionally, what alternative tools are potentially available to replace in vivo studies in these contexts? This commentary explores how veterinary research may improve efforts to meet the principles of the 3R’s by integrating alternative in vitro and in silico models early in the investigative process and utilizing specialized tools within the target veterinary population during clinical trials.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.